Feb 14 |
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
|
Feb 5 |
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
|
Jan 30 |
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|
Jan 3 |
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024
|
Nov 16 |
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis
|
Nov 15 |
Chemomab jumps on FDA Fast Track tag for liver disease therapy
|
Nov 15 |
Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis
|
Nov 13 |
Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023
|
Nov 9 |
Chemomab Therapeutics GAAP EPS of $0.017
|
Nov 9 |
Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
|